Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Dinardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Schuh, A. C.; Fernandez, P. M.; Odenike, O.; Kantarjian, H. M.; Stone, R. M.; Collins, R.; Martinelli, G.; Arnan, M.; Wu, B.; Koralek, D. O.; Van Oostendorp, J.; Gong, J.; MacBeth, K. J.; Vyas, P. |
| Abstract Title: | Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 389s |
| Language: | English |
| ACCESSION: | WOS:000442916002540 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.7042 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7042 -- Source: Wos |
